Serum Choline, Leptin and Interleukin-6 Levels in Fibromyalgia Syndrome-induced Pain: a Case-control Study

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Date 2025 Feb 1

PMID 39893410

Authors

Elif Baris

Izel Topaloglu

Elif Akalin

Emre Hamurtekin

Seray Kabaran

Ayse Gelal

Reyhan Ucku

Mualla Aylin Arici

Affiliations

Soon will be listed here.

Abstract

Background: Fibromyalgia Syndrome (FMS) predominantly affects middle-aged women, characterized by musculoskeletal pain, fatigue, and cognitive issues. Choline, an endogenous molecule, may influence FMS due to its analgesic and anti-inflammatory properties. This study compared choline, leptin, and interleukin-6 (IL-6) levels in FMS patients and controls and examining their association with pain severity.

Methods: Volunteers with FMS were clinically diagnosed at a Physical Medicine and Rehabilitation Department. The control group included pain-free volunteers. Pain severity was gauged using a numeric scale, dietary choline intake through a questionnaire. Serum choline, leptin and (interleukin)IL-6 levels were measured from fasting blood samples of volunteers with enzyme-linked immunosorbent assays (ELISA).

Results: All FMS patients (n = 38) and healthy volunteers (n = 38) were female. Pain score in patients with FMS was 7.6 ± 0.2. Dietary choline intake was lower in patients with FMS than the controls (p = 0.036). Serum choline and leptin levels were lower in the FMS group compared to control (p = 0.03). Serum IL-6 levels were higher in the FMS group than in the control (p < 0.001). There was weak positive correlation between IL-6 levels and pain scores and there were no correlation between leptin levels and pain scores in FMS.

Conclusions: This research highlights FMS's complex nature, involving neurochemical, immunological, and nutritional factors. It suggests the significance of choline's anti-inflammatory effect, leptin's metabolic function, and IL-6's role in FMS pathology. The results suggest that reduced dietary choline might influence serum choline, leptin, and IL-6 levels, potentially impacting FMS-related pain. This points to the potential of supplementary choline intake in FMS management.

Trial Registration: Not applicable (Non-interventional study).

References

Fayed N, Garcia-Campayo J, Magallon R, Andres-Bergareche H, Luciano J, Andres E . Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther. 2010; 12(4):R134. PMC: 2945024. DOI: 10.1186/ar3072. View

Donaldson M, Speight N, Loomis S . Fibromyalgia syndrome improved using a mostly raw vegetarian diet: an observational study. BMC Complement Altern Med. 2001; 1:7. PMC: 57816. DOI: 10.1186/1472-6882-1-7. View

Martinez-Lavin M . Centralized nociplastic pain causing fibromyalgia: an emperor with no cloths?. Clin Rheumatol. 2022; 41(12):3915-3917. PMC: 9561334. DOI: 10.1007/s10067-022-06407-5. View

Abbas M, Rahman S . Effects of alpha-7 nicotinic acetylcholine receptor positive allosteric modulator on lipopolysaccharide-induced neuroinflammatory pain in mice. Eur J Pharmacol. 2016; 783:85-91. DOI: 10.1016/j.ejphar.2016.05.003. View

Napadow V, LaCount L, Park K, As-Sanie S, Clauw D, Harris R . Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis Rheum. 2010; 62(8):2545-55. PMC: 2921024. DOI: 10.1002/art.27497. View

Kosek E, Altawil R, Kadetoff D, Finn A, Westman M, Le Maitre E . Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain--interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis. J Neuroimmunol. 2015; 280:49-55. PMC: 4372266. DOI: 10.1016/j.jneuroim.2015.02.002. View

Ohgidani M, Kato T, Hosoi M, Tsuda M, Hayakawa K, Hayaki C . Fibromyalgia and microglial TNF-α: Translational research using human blood induced microglia-like cells. Sci Rep. 2017; 7(1):11882. PMC: 5605512. DOI: 10.1038/s41598-017-11506-4. View

Cobos-Palacios L, Munoz-Ubeda M, Gallardo-Escribano C, Ruiz-Moreno M, Vilches-Perez A, Vargas-Candela A . Adipokines Profile and Inflammation Biomarkers in Prepubertal Population with Obesity and Healthy Metabolic State. Children (Basel). 2022; 9(1). PMC: 8774044. DOI: 10.3390/children9010042. View

Bjorklund G, Dadar M, Chirumbolo S, Aaseth J . Fibromyalgia and nutrition: Therapeutic possibilities?. Biomed Pharmacother. 2018; 103:531-538. DOI: 10.1016/j.biopha.2018.04.056. View

10.

Achenbach J, Rhein M, Glahn A, Frieling H, Karst M . Leptin promoter methylation in female patients with painful multisomatoform disorder and chronic widespread pain. Clin Epigenetics. 2022; 14(1):13. PMC: 8783406. DOI: 10.1186/s13148-022-01235-5. View

11.

Bagdas D, Ak Sonat F, Hamurtekin E, Sonal S, Gurun M . The antihyperalgesic effect of cytidine-5'-diphosphate-choline in neuropathic and inflammatory pain models. Behav Pharmacol. 2011; 22(5-6):589-98. DOI: 10.1097/FBP.0b013e32834a1efb. View

12.

Heidari F, Afshari M, Moosazadeh M . Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis. Rheumatol Int. 2017; 37(9):1527-1539. DOI: 10.1007/s00296-017-3725-2. View

13.

Petrou M, Harris R, Foerster B, McLean S, Sen A, Clauw D . Proton MR spectroscopy in the evaluation of cerebral metabolism in patients with fibromyalgia: comparison with healthy controls and correlation with symptom severity. AJNR Am J Neuroradiol. 2008; 29(5):913-8. PMC: 8128570. DOI: 10.3174/ajnr.A0959. View

14.

Giorgi V, Bazzichi L, Batticciotto A, Pellegrino G, Di Franco M, Sirotti S . Fibromyalgia: one year in review 2023. Clin Exp Rheumatol. 2023; 41(6):1205-1213. DOI: 10.55563/clinexprheumatol/257e99. View

15.

Audoux C, Estrada-Barranco C, Martinez-Pozas O, Gozalo-Pascual R, Montano-Ocana J, Garcia-Jimenez D . What Concept of Manual Therapy Is More Effective to Improve Health Status in Women with Fibromyalgia Syndrome? A Study Protocol with Preliminary Results. Int J Environ Res Public Health. 2023; 20(2). PMC: 9858983. DOI: 10.3390/ijerph20021061. View

16.

Bartolini A, Ghelardini C, Fantetti L, Malcangio M, Malmberg-Aiello P, GIOTTI A . Role of muscarinic receptor subtypes in central antinociception. Br J Pharmacol. 1992; 105(1):77-82. PMC: 1908635. DOI: 10.1111/j.1476-5381.1992.tb14213.x. View

17.

Wang Y, Su D, Wang R, Liu Y, Wang H . Antinociceptive effects of choline against acute and inflammatory pain. Neuroscience. 2005; 132(1):49-56. DOI: 10.1016/j.neuroscience.2004.12.026. View

18.

Kiyici S, Filiz Basaran N, Cavun S, Savci V . Central injection of CDP-choline suppresses serum ghrelin levels while increasing serum leptin levels in rats. Eur J Pharmacol. 2015; 764:264-270. DOI: 10.1016/j.ejphar.2015.07.014. View

19.

Hone A, McIntosh J . Nicotinic acetylcholine receptors: Therapeutic targets for novel ligands to treat pain and inflammation. Pharmacol Res. 2023; 190:106715. PMC: 10691827. DOI: 10.1016/j.phrs.2023.106715. View

20.

Mendieta D, de la Cruz-Aguilera D, Barrera-Villalpando M, Becerril-Villanueva E, Arreola R, Hernandez-Ferreira E . IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol. 2015; 290:22-5. DOI: 10.1016/j.jneuroim.2015.11.011. View